133 related articles for article (PubMed ID: 35278028)
1. mRNA sequencing analysis and growth inhibitory effects of palbociclib on cell lines from canine histiocytic proliferative disorders.
Hirabayashi M; Chambers JK; Tani A; Tomiyasu H; Motegi T; Rimpo K; Nakayama H; Uchida K
Vet Comp Oncol; 2022 Sep; 20(3):587-601. PubMed ID: 35278028
[TBL] [Abstract][Full Text] [Related]
2. Establishment and characterisation of cell lines and xenograft mouse models of canine systemic histiocytosis and disseminated histiocytic sarcoma.
Hirabayashi M; Chambers JK; Kishimoto TE; Nguyen SV; Ishikawa Y; Rimpo K; Nakayama H; Uchida K
Vet Comp Oncol; 2022 Jun; 20(2):465-475. PubMed ID: 34907644
[TBL] [Abstract][Full Text] [Related]
3. A review of histiocytic diseases of dogs and cats.
Moore PF
Vet Pathol; 2014 Jan; 51(1):167-84. PubMed ID: 24395976
[TBL] [Abstract][Full Text] [Related]
4. [Reactive and neoplastic histiocytic diseases in the dog].
Schwens Ch; Thom N; Moritz A
Tierarztl Prax Ausg K Kleintiere Heimtiere; 2011; 39(3):176-90. PubMed ID: 22143627
[TBL] [Abstract][Full Text] [Related]
5. Histiocytic Diseases.
Moore PF
Vet Clin North Am Small Anim Pract; 2023 Jan; 53(1):121-140. PubMed ID: 36270835
[TBL] [Abstract][Full Text] [Related]
6. Canine hemophagocytic histiocytic sarcoma: a proliferative disorder of CD11d+ macrophages.
Moore PF; Affolter VK; Vernau W
Vet Pathol; 2006 Sep; 43(5):632-45. PubMed ID: 16966440
[TBL] [Abstract][Full Text] [Related]
7. Descriptive Analysis of Histiocytic and Dendritic Cell Neoplasms: A Single-Institution Experience.
Kim HM; Yang WI; Lyu CJ; Hahn SM; Yoon SO
Yonsei Med J; 2020 Sep; 61(9):774-779. PubMed ID: 32882761
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the drug sensitivity and expression of 16 drug resistance-related genes in canine histiocytic sarcoma cell lines.
Asada H; Tomiyasu H; Goto-Koshino Y; Fujino Y; Ohno K; Tsujimoto H
J Vet Med Sci; 2015 Jun; 77(6):677-84. PubMed ID: 25715778
[TBL] [Abstract][Full Text] [Related]
9. PTPN11 mutations in canine and human disseminated histiocytic sarcoma.
Hédan B; Rault M; Abadie J; Ulvé R; Botherel N; Devauchelle P; Copie-Bergman C; Cadieu E; Parrens M; Alten J; Zalcman EL; Cario G; Damaj G; Mokhtari K; Le Loarer F; Coulomb-Lhermine A; Derrien T; Hitte C; Bachelot L; Breen M; Gilot D; Blay JY; Donadieu J; André C
Int J Cancer; 2020 Sep; 147(6):1657-1665. PubMed ID: 32212266
[TBL] [Abstract][Full Text] [Related]
10. Localized and disseminated histiocytic sarcoma of dendritic cell origin in dogs.
Affolter VK; Moore PF
Vet Pathol; 2002 Jan; 39(1):74-83. PubMed ID: 12102221
[TBL] [Abstract][Full Text] [Related]
11. Effect of dasatinib in a xenograft mouse model of canine histiocytic sarcoma and in vitro expression status of its potential target EPHA2.
Ito K; Miyamoto R; Tani H; Kurita S; Kobayashi M; Tamura K; Bonkobara M
J Vet Pharmacol Ther; 2018 Feb; 41(1):e45-e48. PubMed ID: 28833247
[TBL] [Abstract][Full Text] [Related]
12. High frequency of clonal IG and T-cell receptor gene rearrangements in histiocytic and dendritic cell neoplasms.
Huang W; Qiu T; Zeng L; Zheng B; Ying J; Feng X
Oncotarget; 2016 Nov; 7(48):78355-78362. PubMed ID: 27823979
[TBL] [Abstract][Full Text] [Related]
13. MUM1/IRF4 immunolabeling of neoplastic Langerhans histiocytes in a putative case of canine Langerhans cell histiocytosis.
Klosowski ML; Hughes KL; Moore AR
Vet Clin Pathol; 2023 Dec; 52(4):670-675. PubMed ID: 37528067
[TBL] [Abstract][Full Text] [Related]
14. Establishment of cell line and in vivo mouse model of canine Langerhans cell histiocytosis.
Son NV; Uchida K; Thongtharb A; Chambers JK; Kishimoto TE; Tomiyasu H; Ohmi A; Tsujimoto H; Nakayama H
Vet Comp Oncol; 2019 Sep; 17(3):345-353. PubMed ID: 30884050
[TBL] [Abstract][Full Text] [Related]
15. Molecular characterization of canine SHP2 mutants and anti-tumour effect of SHP2 inhibitor, SHP099, in a xenograft mouse model of canine histiocytic sarcoma.
Tani H; Miyamoto R; Nagashima T; Michishita M; Tamura K; Bonkobara M
Vet Comp Oncol; 2022 Mar; 20(1):109-117. PubMed ID: 34241941
[TBL] [Abstract][Full Text] [Related]
16. Identification of dasatinib as an in vitro potent growth inhibitor of canine histiocytic sarcoma cells.
Ito K; Kuroki S; Kobayashi M; Ono K; Washizu T; Bonkobara M
Vet J; 2013 Jun; 196(3):536-40. PubMed ID: 23369384
[TBL] [Abstract][Full Text] [Related]
17. Influence of a survivin suppressor YM155 on the chemoresistance of canine histiocytic sarcoma cells.
Yamazaki H; Takagi S; Hosoya K; Okumura M
Vet J; 2015 Sep; 205(3):375-80. PubMed ID: 26048444
[TBL] [Abstract][Full Text] [Related]
18. Variations in Histiocytic Differentiation of Cell Lines From Canine Cerebral and Articular Histiocytic Sarcomas.
Thongtharb A; Uchida K; Chambers JK; Nakayama H
Vet Pathol; 2017 May; 54(3):395-404. PubMed ID: 28178429
[TBL] [Abstract][Full Text] [Related]
19. Serum level of apoptosis inhibitor of macrophage in dogs with histiocytic sarcoma and its association with the disease.
Uchida M; Matsumiya Y; Tsuboi M; Uchida K; Nakagawa T; Fujii W; Kobayashi T; Tsujimoto H; Ohmi A; Tomiyasu H; Motegi T; Maeda S; Momoi Y; Yonezawa T
Vet Comp Oncol; 2023 Sep; 21(3):391-400. PubMed ID: 37088561
[TBL] [Abstract][Full Text] [Related]
20. In vitro study to assess the efficacy of CDK4/6 inhibitor Palbociclib (PD-0332991) for treating canine mammary tumours.
Schoos A; Knab VM; Gabriel C; Tripolt S; Wagner DA; Bauder B; Url A; Fux DA
Vet Comp Oncol; 2019 Dec; 17(4):507-521. PubMed ID: 31207004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
